Impavido Approved to Treat Tropical Parasitic Disease
THURSDAY, March 20, 2014 (HealthDay News) -- Impavido (miltefosine) has been approved by the U.S. Food and Drug Administration to treat adults with leishmaniasis, a tropical disease caused by a parasite that's transmitted by the bites of sand flies.
Most Americans who contract the disease do so traveling overseas, the agency said in a news release.
The drug's safety and effectiveness were evaluated in clinical trials involving more than 700 people. Impavido's label will include a boxed warning that the medication could harm a developing fetus and shouldn't be taken by pregnant women.
Common side effects include nausea, vomiting, diarrhea, headache, loss of appetite, dizziness, abdominal pain, itching, fatigue and elevated liver enzymes, the FDA said.
The drug is produced by Paladin Therapeutics, based in Montreal.
The U.S. Centers for Disease Control and Prevention has more about leishmaniasisRelated Articles
- Ruconest Approved for Rare Genetic Disease
July 17, 2014
- Beleodaq Approved for Aggressive non-Hodgkin Lymphoma
July 03, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright ©2013 HealthDay. All rights reserved.